CEACAM8 and B-cell non-Hodgkin lymphoma: Accordingly, among aggressive B-cell NHL patients, those affected by a particularly unfavorable type of diffuse large B-cell lymphoma (DLBCL) (i.e. “double” and “triple expressor” DLBCLs, n = 7) [30], had a significantly higher percentage of circulating CD66b+CD33dimHLA-DR− cells as compared to the remaining 47 DLBCL patients [7.59 (2.57–46.21) vs 2.14 (0.25–70.92), p = 0.045] (O.M. and C.T. personal communication).